TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Inclusion criteria:

   - Patients must have histologically or cytologically confirmed diagnosis (from primary
   lesion and/or lymph nodes) of Squamous Cell Cancer of the oropharynx, hypopharynx or
   larynx (For patients with oropharynx primary, the tumor must be negative for p16 by
   immunohistochemistry).

   - Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b, N2c
   or N3 p16 negative oropharynx cancer or T1-2 any N+ hypopharynx cancer) including no
   distant metastases.

   - History/Physical examination by a Radiation Oncologist and Medical oncologist prior to
   entering the study.

   - Examination by an ears, nose, throat (ENT) or Head & Neck Surgeon including
   laryngopharyngoscopy prior to entering the study.

   - Patients must have a chest CT scan, or positron emission tomography (PET)/CT scan to
   rule out metastatic disease

   - Patients must have a contrast enhanced CT scan or MRI or PET/CT scan of the tumor site
   and neck nodes prior to entering the study.

   - Patients must have an EKG and echocardiogram (ECHO) or multigated acquisition (MUGA)
   scan prior to entering the study.

   - Patients must have Zubrod Performance Status of 0-1.

   - Patients must be ≥ 18 years of age.

   - Patients must have normal organ and marrow function as defined below:

      - Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

      - Platelets ≥ 100,000 cells/mm3

      - Hemoglobin ≥ 8.0 g/dl

      - Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min

      - Total bilirubin < 2 x the institutional upper limit of normal

      - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the
      institutional upper limit of normal

   - Patient must have magnesium, calcium, glucose, potassium and sodium levels within
   normal limits

   - Women of childbearing potential must have a negative pregnancy test prior to
   registration.

   - Patients of reproductive potential must practice effective contraception while on
   study and for at least 60 calendar days following treatment.

   - All patients must sign an informed consent prior to enrollment.

   - Patients must comply with the treatment plan and follow-up schedule.

Exclusion criteria:

   - Patients with simultaneous primaries or bilateral tumors.

   - Patients who have had gross total excision of the primary tumor.

   - Patients with initial surgical treatment, radical or modified neck dissection.

   - Patients who received prior systemic chemotherapy for the study cancer.

   - Patients who received prior radiotherapy to the region of the study cancer that would
   result in overlap of radiation therapy fields.

   - Patients with primary tumor of oral cavity, nasopharynx, sinuses or salivary glands.

   - Prior allergic reaction to the study drugs.

   - Patients who have had prior therapy that specifically and directly targets the
   epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2
   (HER2) pathway.

   - Patients who have current active hepatic or biliary disease (with exception of
   patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver
   disease per investigator assessment);

   - Pregnant women or sexually active patients not willing or able to use medically
   acceptable forms of contraceptive method while on treatment.

   - Patients with severe, active co-morbidity, defined as follows:

      - Uncontrolled cardiac disease, such as uncontrolled hypertension, unstable angina,
      and/or congestive heart failure requiring hospitalization within the last 6
      months

      - Transmural myocardial infarction within the last 6 months

      - Left ventricular ejection fraction < 45%

      - Acute bacterial or fungal infection requiring intravenous antibiotics at the time
      of registration

      - Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
      requiring hospitalization or precluding study therapy within 30 calendar days
      prior to registration

      - Hepatic insufficiency resulting in clinical jaundice and/or Coagulation defects

      - Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease
      Control and Prevention (CDC) definition